PAH Exercise Study (NCT06941441)
Remotely-Monitored Exercise to Enhance Functional Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) Initiating Sotatercept Therapy: A Single-site Feasibility Study
🩺 Plain-English Summary (8th-Grade Level)
Ten patients with PAH who are stable and eligible to initiate sotatercept therapy will participate in a 26 week study that consists of a 24-week intervention period where patients will receive complimentary sotatercept as prescribed, plus a tailored, progressive home exercise program with wrist-worn fitness tracker and oxygen saturation monitoring.
Who can join: Review the eligibility criteria below.
Location: University of Washington — Seattle, Washington
Age range: 18 Years
🧪 Interventions in This Study
- Home exercise program (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Washington — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (206) 616-8601
Email: cechild@uw.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension (PAH)
- A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag — Columbus, Georgia
- Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH) — Tucson, Arizona
- Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept. — Tucson, Arizona
- Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) — Aurora, Colorado
- A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension — Stanford, California
Explore by condition: All Pulmonary Arterial Hypertension (PAH) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.